دورية أكاديمية
أعرض في EDS

Molecular Investigation of miRNA Biomarkers as Chemoresistance Regulators in Melanoma: A Protocol for Systematic Review and Meta-Analysis.

التفاصيل البيبلوغرافية
العنوان: Molecular Investigation of miRNA Biomarkers as Chemoresistance Regulators in Melanoma: A Protocol for Systematic Review and Meta-Analysis.
المؤلفون: Shaw P; Department of Artificial Intelligence, Nanjing University of Information Science and Technology (NUIST), Nanjing 211544, China.; Menzies School of Health Research, Darwin 0810, Australia., Raymond G; Northern Territory Medical Program, CDU Campus, Flinders University, Ellengowan Drive, Darwin 0909, Australia., Tzou KS; Department of Radiation Oncology, Mayo Clinic Florida, 4500 San Pablo Road S, Jacksonville, FL 32224, USA., Baxi S; Genesis Care Gold Coast Radiation Oncologist, John Flynn Hospital, 42 Inland Drive, Tugun 4224, Australia., Mani RR; Department of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, UCSI University Kuala Lumpur (South Wing), No.1, Jalan Menara Gading, UCSI Heights, Cheras, Kuala Lumpur 56000, Malaysia., Kumar Govind S; Department of Parasitology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia., Chandramoorthy HC; Stem Cells and Regenerative Medicine Unit, Department of Microbiology and Clinical Parasitology, College of Medicine, King Khalid University, Abha 61421, Saudi Arabia., Sivanandy P; Department of Pharmacy Practice, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia., Rajagopal M; Faculty of Pharmaceutical Sciences, UCSI University Kuala Lumpur (South Wing), No.1, Jalan Menara Gading, UCSI Heights, Cheras, Kuala Lumpur 56000, Malaysia., Samiappan S; Department of Biochemistry, Bharathiar University, Coimbatore 641046, India., Krishnan S; Department of Radiation Oncology, Mayo Clinic Florida, 4500 San Pablo Road S, Jacksonville, FL 32224, USA., Jayaraj R; Northern Territory Institute of Research and Training, Darwin 0909, Australia.
المصدر: Genes [Genes (Basel)] 2022 Jan 08; Vol. 13 (1). Date of Electronic Publication: 2022 Jan 08.
نوع المنشور: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101551097 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4425 (Electronic) Linking ISSN: 20734425 NLM ISO Abbreviation: Genes (Basel) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel : MDPI
مواضيع طبية MeSH: Drug Resistance, Neoplasm* , Meta-Analysis as Topic*, Biomarkers, Tumor/*genetics , Melanoma/*drug therapy , MicroRNAs/*genetics , Systematic Reviews as Topic/*methods, Humans ; Melanoma/genetics ; Melanoma/pathology
مستخلص: Introduction: Melanoma is a global disease that is predominant in Western countries. However, reliable data resources and comprehensive studies on the theragnostic efficiency of miRNAs in melanoma are scarce. Hence, a decisive study or comprehensive review is required to collate the evidence for profiling miRNAs as a theragnostic marker. This protocol details a comprehensive systematic review and meta-analysis on the impact of miRNAs on chemoresistance and their association with theragnosis in melanoma. Methods and analysis: The articles will be retrieved from online bibliographic databases, including Cochrane Review, EMBASE, MEDLINE, PubMed, Scopus, Science Direct, and Web of Science, with different permutations of 'keywords'. To obtain full-text papers of relevant research, a stated search method will be used, along with selection criteria. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Protocols 2015 (PRISMA-P) standards were used to create this study protocol. The hazard ratio (HR) with a 95% confidence interval will be analyzed using Comprehensive Meta-Analysis (CMA) software 3.0. (CI). The pooled effect size will be calculated using a random or fixed-effects meta-analysis model. Cochran's Q test and the I2 statistic will be used to determine heterogeneity. Egger's bias indicator test, Orwin's and the classic fail-safe N tests, the Begg and Mazumdar rank collection test, and Duval and Tweedie's trim and fill calculation will all be used to determine publication bias. The overall standard deviation will be evaluated using Z-statistics. Subgroup analyses will be performed according to the melanoma participants' clinicopathological and biological characteristics and methodological factors if sufficient studies and retrieved data are identified and available. The source of heterogeneity will be assessed using a meta-regression analysis. A pairwise matrix could be developed using either a pairwise correlation or expression associations of miRNA with patients' survival for the same studies.
References: J Dermatol. 2003 Feb;30(2):123-31. (PMID: 12692379)
World J Surg Oncol. 2018 Jun 18;16(1):111. (PMID: 29914529)
Cytokine Growth Factor Rev. 2017 Aug;36:39-48. (PMID: 28551321)
BMJ. 2015 Jan 02;350:g7647. (PMID: 25555855)
Cancer Manag Res. 2018 Sep 13;10:3501-3503. (PMID: 30271198)
J Invest Dermatol. 2016 Jan;136(1):245-254. (PMID: 26763444)
Cancer Metastasis Rev. 2001;20(1-2):3-11. (PMID: 11831644)
Oncogenesis. 2017 May 1;6(5):e326. (PMID: 28459431)
BMC Bioinformatics. 2012 Jun 25;13 Suppl 10:S7. (PMID: 22759431)
Cell. 2012 Nov 21;151(5):1068-82. (PMID: 23142051)
Gene. 2017 Sep 5;627:420-427. (PMID: 28669929)
BMJ Open. 2018 Aug 20;8(8):e020014. (PMID: 30127047)
Curr Pharm Des. 2017;23(12):1845-1859. (PMID: 28231756)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)
Dis Markers. 2018 Oct 22;2018:6904569. (PMID: 30425753)
Cancer Lett. 2017 Mar 1;388:107-117. (PMID: 27940128)
J Comput Biol. 1999 Fall-Winter;6(3-4):281-97. (PMID: 10582567)
PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072)
J Biol Chem. 2011 May 13;286(19):16606-14. (PMID: 21454583)
Mol Diagn Ther. 2019 Feb;23(1):65-82. (PMID: 30726546)
Biometrics. 1994 Dec;50(4):1088-101. (PMID: 7786990)
Oral Oncol. 2019 Feb;89:159-160. (PMID: 30606668)
Br J Cancer. 2018 Mar 6;118(5):e11. (PMID: 29449675)
Carcinogenesis. 2009 Oct;30(10):1735-43. (PMID: 19706646)
Biometrics. 2000 Jun;56(2):455-63. (PMID: 10877304)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1051-5. (PMID: 16973303)
J Clin Oncol. 2011 Aug 1;29(22):3085-96. (PMID: 21383288)
Cancer Res. 2007 Sep 15;67(18):8699-707. (PMID: 17875710)
Syst Rev. 2018 Oct 2;7(1):150. (PMID: 30285880)
Oral Oncol. 2019 Feb;89:153-154. (PMID: 30612934)
Oncol Rep. 2017 Oct;38(4):2051-2061. (PMID: 28849187)
BMC Cancer. 2014 Nov 07;14:819. (PMID: 25376700)
Biol Chem. 2017 Jul 26;398(8):929-938. (PMID: 28095367)
J Clin Oncol. 1998 Feb;16(2):670-82. (PMID: 9469357)
Cancer Manag Res. 2018 Oct 16;10:4669-4670. (PMID: 30410400)
Prostate Int. 2013;1(1):3-9. (PMID: 24223395)
Lancet. 2004 Apr 24;363(9418):1346-53. (PMID: 15110491)
J Natl Cancer Inst. 2012 Apr 4;104(7):528-40. (PMID: 22395642)
Oral Oncol. 2019 Mar;90:137-138. (PMID: 30579681)
Oral Oncol. 2018 Nov;86:312-313. (PMID: 30262125)
J Photochem Photobiol B. 2001 Oct;63(1-3):8-18. (PMID: 11684447)
Front Physiol. 2019 Jan 22;9:1896. (PMID: 30723420)
Nature. 2005 Jun 9;435(7043):834-8. (PMID: 15944708)
JAMA. 2000 Apr 19;283(15):2008-12. (PMID: 10789670)
Oral Oncol. 2019 Mar;90:139-140. (PMID: 30579680)
Expert Opin Ther Targets. 2017 Nov;21(11):1063-1075. (PMID: 28994330)
Int J Cancer. 1996 Jul 3;67(1):24-8. (PMID: 8690520)
Nature. 1997 Nov 27;390(6658):335-6. (PMID: 9389468)
Indian J Pathol Bacteriol. 1968 Jul;11(3):183-9. (PMID: 5760889)
Stat Med. 1999 Oct 30;18(20):2693-708. (PMID: 10521860)
Medicine (Baltimore). 2018 Dec;97(52):e13680. (PMID: 30593138)
Oncogene. 2008 Nov 6;27(52):6698-706. (PMID: 18679415)
J Cancer Res Ther. 2009 Jul-Sep;5(3):173-80. (PMID: 19841558)
Photochem Photobiol. 1990 Jun;51(6):765-79. (PMID: 2195564)
Mol Diagn Ther. 2018 Dec;22(6):653-669. (PMID: 30259393)
Oral Oncol. 2018 Sep;84:121-122. (PMID: 30075910)
Oncol Rev. 2017 Mar 24;11(1):326. (PMID: 28382191)
Prostate. 2017 Jun;77(9):1020-1028. (PMID: 28485104)
Stat Med. 2002 Jun 15;21(11):1513-24. (PMID: 12111917)
معلومات مُعتمدة: RE/18/4/34215 United Kingdom BHF_ British Heart Foundation; CL-2020-16-001 United Kingdom DH_ Department of Health
فهرسة مساهمة: Keywords: chemoresistance; chemosensitivity; melanoma; meta-analysis; miRNAs; protocol; systematic review
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (MicroRNAs)
تواريخ الأحداث: Date Created: 20220121 Date Completed: 20220222 Latest Revision: 20220222
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8775297
DOI: 10.3390/genes13010115
PMID: 35052456
قاعدة البيانات: MEDLINE
الوصف
تدمد:2073-4425
DOI:10.3390/genes13010115